Seminars in Hematology
Volume 44 , Pages S21-S25 , April 2007

New Trends in Iron Chelation: Impacting Outcomes

  • Ali Taher

      Affiliations

    • Department of Internal Medicine, American University of Beirut Medical Center, Beirut, Lebanon.
    • Corresponding Author InformationAddress correspondence to Professor Ali Taher, MD, Department of Internal Medicine, American University of Beirut, PO Box 11-0236, Beirut 1107 2020, Lebanon.
    • ,
  • Norbert Gattermann

      Affiliations

    • Department of Haematology, Oncology and Clinical Immunology, Heinrich-Heine University, Düsseldorf, Germany.

References 

  1. Piga A, Galanello R, Forni G-L, et al. Randomized phase II trial of deferasirox (Exjade, ICL670), a once-daily, orally-administered iron chelator, in comparison to deferoxamine in thalassemia patients with transfusional iron overload. Haematologica. 2006;91:873–880
  2. Brittenham GM, Griffith PM, Nienhuis AW, et al. Efficacy of deferoxamine in preventing complications of iron overload in patients with thalassemia major. N Engl J Med. 1994;331:567–573
  3. Davis BA, Porter JB. Long-term outcome of continuous 24-hour deferoxamine infusion via indwelling intravenous catheters in high-risk β-thalassemia. Blood. 2000;95:1229–1236
  4. Taher A, El-Beshlawy A, Al Jefri A, et al. Deferasirox (Exjade®, ICL670) treatment of inadequately chelated β-thalassemia patients from the Middle East: The ESCALATOR trial. Blood. 2005;106(11):3840;abstr
  5. Gattermann N, Porter J, Lopes LF, et al. Consensus statement on iron overload in myelodysplastic syndromes. Hematol Oncol Clin North Am. 2005;19(suppl 1):18–25
  6. Alessandrino EP, Amadori S, Barosi G, et al. Evidence- and consensus-based practice guidelines for the therapy of primary myelodysplastic syndromes (A statement from the Italian Society of Hematology). Haematologica. 2002;87:1286–1306
  7. Greenberg PL, Baer MR, Bennett JM, et al. Myelodysplastic syndromes clinical practice guidelines in oncology. J Natl Compr Cancer Network. 2006;4:58–77
  8. Gattermann N. Clinical consequences of iron overload in myelodysplastic syndromes and treatment with chelators. Hematol Oncol Clin North Am. 2005;19(suppl 1):13–17
  9. Cappellini MD, Cohen A, Piga A, et al. A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with β-thalassemia. Blood. 2006;107:3455–3462
  10. Vichinsky E, Fischer R, Fung E, et al. A randomized, controlled phase II trial in sickle cell disease patients with chronic iron overload demonstrates that the once-daily oral iron chelator deferasirox (Exjade®, ICL670) is well tolerated and reduces iron burden. Blood. 2005;106(11):313;abstr
  11. Kattamis C, Kilinc Y, Fattoum S, et al. Deferasirox (Exjade®, ICL670) demonstrates iron chelating efficacy related to transfusional iron intake in pediatric patients. Blood. 2005;106(11):2692;abstr
  12. Vichinsky E, Fischer R, Pakbaz Z, et al. Satisfaction and convenience of chelation therapy in patients with sickle cell disease (SCD): Comparison between deferasirox (Exjade®, ICL670) and deferoxamine (DFO). Blood. 2005;106(11):2334;abstr
  13. Cappellini MD, Bejaoui M, Agaoglu L, et al. Patient satisfaction with deferasirox (Exjade®, ICL670) an oral form of chelation therapy versus deferoxamine an infused chelation therapy. Blood. 2005;106(11):2704;abstr
  14. Malcovati L, Della Porta MG, Pascutto C, et al. Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: A basis for clinical decision making. J Clin Oncol. 2005;23:7594–7603

PII: S0037-1963(07)00054-6

doi: 10.1053/j.seminhematol.2007.03.003

Seminars in Hematology
Volume 44 , Pages S21-S25 , April 2007

Article Tools

* Image Usage & Resolution